Infant Bacterial Therapeutics AB IFTBF
$6.85
Last Updated: Jul 07, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
IFTBF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Infant Bacterial Therapeutics AB is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
I
Infant Bacterial Therapeutics AB. Stock Analysis IFTBF
United States Health Care Micro Cap Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Infant Bacterial Therapeutics AB (IFTBF) Chart
Financial Metrics & Statements of Infant Bacterial Therapeutics AB (IFTBF)
FAQ's for Infant Bacterial Therapeutics AB (IFTBF)
- As of August 2026, Infant Bacterial Therapeutics AB IFTBF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Infant Bacterial Therapeutics AB using these criteria to determine its compliance status.
- Muslim investors may consider investing in Infant Bacterial Therapeutics AB if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Infant Bacterial Therapeutics AB by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Infant Bacterial Therapeutics AB may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Infant Bacterial Therapeutics AB on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Infant Bacterial Therapeutics AB (IFTBF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
